BEVERLY DRISKILL: Open Payments
NPI 1689762122 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$655 in 29 payments from 10 companies in 2025. Trend: 2023 $849 · 2024 $80 · 2025 $655
Food & beverage: $655
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 8 | $211 |
| Neurocrine BioSciences, Inc. | 4 | $109 |
| Otsuka America Pharmaceutical, Inc. | 4 | $75 |
| Alkermes, Inc. | 2 | $61 |
| Teva Pharmaceuticals USA, Inc. | 3 | $53 |
| Supernus Pharmaceuticals, Inc. | 3 | $43 |
| ABBVIE INC. | 2 | $38 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Janssen Pharmaceuticals, Inc | 1 | $24 |
| Lundbeck LLC | 1 | $14 |
Products named: COBENFY, INGREZZA, ARISTADA, Qelbree, ABILIFY ASIMTUFII, VRAYLAR, UZEDY, REXULTI.
Industry payments across NV — which companies pay providers there.
